DNA Link Inc Cash Flow Conversion Efficiency
DNA Link Inc cash flow conversion efficiency. Based on the latest financial reports, DNA Link Inc (127120) has a cash flow conversion efficiency ratio of -0.060x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-5.37 Billion ≈ $-3.64 Million USD) by net assets (₩89.37 Billion ≈ $60.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DNA Link Inc stock valuation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of DNA Link Inc (2011–2025)
Cash flow conversion efficiency of DNA Link Inc from 2011 to 2025. This chart illustrates how DNA Link Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View DNA Link Inc (127120) stock price for real-time trading data and today's change.
DNA Link Inc Cash Flow Conversion Ratio Explained
DNA Link Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
DNA Link Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DNA Link Inc ranked by their cash flow conversion efficiency. Review free cash flow generation of DNA Link Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Triductor Technology (Suzhou) Inc.
SHG:688259
|
0.022x |
|
Autolus Therapeutics plc
F:6A3A
|
-0.335x |
|
ITAB Shop Concept AB ser. B
ST:ITAB
|
-0.002x |
|
Alpha Hpa Ltd
AU:A4N
|
-0.030x |
|
Murapol S.A.
WAR:MUR
|
0.179x |
|
Sichuan Etrol Technologies Co Ltd
SHE:300370
|
0.014x |
|
Paslin Digital Technology Co Ltd
SHG:600215
|
0.030x |
|
Tadiran Hldg
TA:TDRN
|
-0.153x |
Annual Cash Flow Conversion Efficiency for DNA Link Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of DNA Link Inc from 2011 to 2025. Also see 127120 total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩68.59 Billion ≈ $46.48 Million |
₩-9.39 Billion ≈ $-6.36 Million |
-0.137x | +49.49% |
| 2024-12-31 | ₩25.03 Billion ≈ $16.96 Million |
₩-6.78 Billion ≈ $-4.60 Million |
-0.271x | -41.54% |
| 2023-12-31 | ₩26.28 Billion ≈ $17.81 Million |
₩-5.03 Billion ≈ $-3.41 Million |
-0.191x | -686.44% |
| 2022-12-31 | ₩27.89 Billion ≈ $18.90 Million |
₩910.27 Million ≈ $616.88K |
0.033x | +116.64% |
| 2021-12-31 | ₩32.77 Billion ≈ $22.21 Million |
₩-6.43 Billion ≈ $-4.36 Million |
-0.196x | -993.88% |
| 2020-12-31 | ₩38.70 Billion ≈ $26.23 Million |
₩849.38 Million ≈ $575.62K |
0.022x | +116.32% |
| 2019-12-31 | ₩9.66 Billion ≈ $6.55 Million |
₩-1.30 Billion ≈ $-880.41K |
-0.134x | -64.54% |
| 2018-12-31 | ₩19.60 Billion ≈ $13.29 Million |
₩-1.60 Billion ≈ $-1.09 Million |
-0.082x | +22.37% |
| 2017-12-31 | ₩23.66 Billion ≈ $16.03 Million |
₩-2.49 Billion ≈ $-1.69 Million |
-0.105x | +94.93% |
| 2016-12-31 | ₩1.82 Billion ≈ $1.23 Million |
₩-3.77 Billion ≈ $-2.55 Million |
-2.076x | -523.69% |
| 2015-12-31 | ₩11.20 Billion ≈ $7.59 Million |
₩-3.73 Billion ≈ $-2.53 Million |
-0.333x | -1698.26% |
| 2014-12-31 | ₩7.73 Billion ≈ $5.24 Million |
₩-143.14 Million ≈ $-97.00K |
-0.019x | +58.15% |
| 2012-12-31 | ₩17.70 Billion ≈ $12.00 Million |
₩-783.00 Million ≈ $-530.63K |
-0.044x | +79.15% |
| 2011-12-31 | ₩11.52 Billion ≈ $7.81 Million |
₩-2.44 Billion ≈ $-1.66 Million |
-0.212x | -- |
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more